Home | GSK US
WEBInclusive leadership hits different. Hear from Rizwan Khokhar, an inclusive leader at GSK's Zebulon location in North Carolina.
Careers | GSK US
WEBAt GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.
Company | GSK US
WEBGSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US.
At a glance | GSK US
WEBAt a glance. Getting Ahead Together means preventing disease as well as treating it. Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies.
Contact us - GSK
WEBContact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for certain GSK products.
Products - GSK US
WEBProducts. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States.
Search jobs | GSK US
WEBGSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG. GSK websites. GSK Global website. Locations selector. Global Behind the science.
Charitable grants - GSK US
WEBGSK IMPACT Awards support and reward small- to mid-sized nonprofit organizations in Greater Philadelphia and in the Triangle Region of North Carolina that are improving community health through the social determinants of health.
Locations | GSK US
WEBGSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG ...
Press releases | GSK US
WEBUS FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit.